Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2:05
Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
8 个月之前
targetedonc.com
Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC | OncLive
Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC | OncLive
11 个月之前
onclive.com
Dr. Wakelee on Explaining Adjuvant Therapy to Patients | OncLive
Dr. Wakelee on Explaining Adjuvant Therapy to Patients | OncLive
2011年9月21日
onclive.com
How Neoadjuvant Therapy Beats Postoperative Chemotherapy
How Neoadjuvant Therapy Beats Postoperative Chemotherapy
2025年1月28日
medscape.com
Dr. Marshall on Changes With Adjuvant Treatment in CRC | OncLive
Dr. Marshall on Changes With Adjuvant Treatment in CRC | OncLive
2021年1月25日
onclive.com
Integrating Durvalumab and Atezolizumab Into Neoadjuvant and Adjuvant Sequencing Strategies for Resectable NSCLC | AJMC
Integrating Durvalumab and Atezolizumab Into Neoadjuvant and Adjuvant Sequencing Strategies for Resectable NSCLC | AJMC
2 个月之前
ajmc.com
Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies | OncLive
Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies | OncLive
2023年7月13日
onclive.com
0:59
Adjuvant Therapy for Treatment of Melanoma
2017年12月28日
curemelanoma.org
2:30
Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence | OncLive
5 个月之前
onclive.com
Oncology and fight against tumors: adjuvant therapy
2023年2月24日
emergency-live.com
KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC
2022年7月12日
vjoncology.com
Dr. Eng on the Role of Adjuvant Chemotherapy in CRC | OncLive
2020年11月16日
onclive.com
Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC | OncLive
11 个月之前
onclive.com
ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuvant Treatments, 1L Metastatic & Anti-PD-1 Refractory Disease"
已浏览 352 次2024年7月5日
vumedi.com
IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC | CancerNetwork
2022年5月13日
cancernetwork.com
New Adjuvant Option Emerges for Node-Positive ER Breast Cancer
1 个月前
medscape.com
6:31
KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2023年12月15日
targetedonc.com
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD | Urology Times
3 个月之前
urologytimes.com
12:49
ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK NSCLC | OncLive
2023年11月17日
onclive.com
Neoadjuvant Therapy in NSCLC: 5-Year Study Unveils Nivolumab’s Curative Potential
7 个月之前
medscape.com
AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC | OncLive
2023年5月19日
onclive.com
Dr. Ali on the Future of Adjuvant Care for HER2 Breast Cancer | OncLive
2018年6月21日
onclive.com
Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC | OncLive
2023年3月10日
onclive.com
3:27
Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2 Early Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2024年1月11日
targetedonc.com
4:01
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
6 个月之前
reachmd.com
KEYNOTE-091 Evaluates Adjuvant Pembrolizumab in Resected Early-Stage NSCLC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
2022年7月19日
targetedonc.com
IASLC Issues Consensus on Neoadjuvant, Adjuvant Treatments in Non–Small Cell Lung Cancer
2024年8月8日
medscape.com
Adjuvant Therapy for Advanced Melanoma
2 个月之前
medscape.com
Treatment Approaches After Adjuvant Osimertinib | OncLive
2021年6月24日
onclive.com
展开